Європейський Союз - данська - EMA (European Medicines Agency)

novartis europharm limited  - brolucizumab - wet macular degeneration - oftalmologiske - beovu er indiceret hos voksne til behandling af neovaskulær (våd) aldersrelateret macula degeneration (amd).

Європейський Союз - данська - EMA (European Medicines Agency)

novo nordisk a/s - somapacitan - vækst - hypofysiske og hypotalamiske hormoner og analoger - sogroya is indicated for the replacement of endogenous growth hormone (gh) in children  aged 3  years and above, and adolescents with growth failure due to growth hormone deficiency (paediatric ghd), and in adults with growth hormone deficiency (adult ghd).

Європейський Союз - данська - EMA (European Medicines Agency)

samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - oftalmologiske - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Європейський Союз - данська - EMA (European Medicines Agency)

swedish orphan biovitrum ab (publ) - pegcetacoplan - hemoglobinuri, paroxysmal - immunosuppressiva - aspaveli is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh) who are anaemic after treatment with a c5 inhibitor for at least 3 months.

Європейський Союз - данська - EMA (European Medicines Agency)

laboratorios farmacéuticos rovi, s.a. - risperidone - skizofreni - psykoleptika - treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone.

Європейський Союз - данська - EMA (European Medicines Agency)

sanofi pasteur - sars-cov-2 prefusion spike delta tm protein, recombinant (b.1.351 strain) - covid-19 virus infection - vacciner - vidprevtyn beta is indicated as a booster for active immunisation to prevent covid-19 in adults who have previously received an mrna or adenoviral vector covid-19 vaccine (see sections 4. 2 og 5. 1 in product information document). brug af denne vaccine bør være i overensstemmelse med de officielle anbefalinger.

Європейський Союз - данська - EMA (European Medicines Agency)

alnylam netherlands b.v. - vutrisiran sodium - amyloid neuropathies, familial - andre narkotika stoffer - treatment of hereditary transthyretin-mediated amyloidosis (hattr amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.

Європейський Союз - данська - EMA (European Medicines Agency)

novo nordisk a/s - insulin aspart - diabetes mellitus - drugs used in diabetes, insulins and analogues for injection, fast-acting - behandling af diabetes mellitus hos voksne, unge og børn i alderen 1 år og derover.

Європейський Союз - данська - EMA (European Medicines Agency)

merial - inaktiveret ibr-virus - immunologiske stoffer til bovidae - kvæg - aktiv immunisering af kvæg for at reducere de kliniske tegn på infektiøs bovin rhinotracheitis (ibr) og feltvirusudskillelse. starten af immunitet er 14 dage og varighed af immunitet er 6 måneder.

Європейський Союз - данська - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - bluetongue-virus serotype-1 antigen, bluetongue virus serotype 8 antigen - immunologiske - sheep; cattle - sheepactive vaccination af får og kvæg for at undgå viraemia og på at reducere kliniske symptomer forårsaget af bluetongue virus serotyper 1, 2, 4 og/ eller 8 (kombination af maksimalt 2 serotyper), aktiv immunisering af får og kvæg for at undgå viraemia og på at reducere kliniske symptomer forårsaget af bluetongue virus serotyper, 1,2, 4 og/ eller 8 (kombination af maksimalt 2 serotyper), aktiv immunisering af får for at forhindre viraemia og på at reducere kliniske symptomer forårsaget af bluetongue virus serotyper 1, 2, 4 og/eller 8 (kombination af maksimalt 2 serotyper). cattleactive vaccination af kvæg for at forhindre viraemia forårsaget af bluetongue virus serotype 1, 2, 4 og/ eller 8, og på at reducere kliniske symptomer forårsaget af bluetongue virus serotyper, når de observeres i denne art: serotype 1, 4 og / eller 8 (kombination af maksimalt 2 serotyper). aktiv immunisering af kvæg for at forhindre viraemia forårsaget af bluetongue virus serotype 1, 2, 4 og/ eller 8, og på at reducere kliniske symptomer forårsaget af bluetongue virus serotyper, når de observeres i denne art: serotype 1, 4 og / eller 8 (kombination af maksimalt 2 serotyper). aktiv immunisering af får og kvæg for at undgå viraemia og på at reducere kliniske symptomer forårsaget af bluetongue virus serotyper 1, 2, 4 og/eller 8 (kombination af maksimalt 2 serotyper).